{
    "clinical_study": {
        "@rank": "77194", 
        "arm_group": {
            "arm_group_label": "Refractory/Recurrent/High Risk Solid Tumors"
        }, 
        "biospec_descr": {
            "textblock": "Blood samples, tumor samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "In this study tumor will be tested for cancer causing gene alterations such as mutations or\n      copy number alterations. This is called tumor profiling. A panel of experts will review the\n      tumor profiling results and determine whether there is a cancer-causing alteration present\n      in the tumor. If there is, the experts will determine if there is a targeted drug available\n      that could counteract this alteration. If there is an alteration identified and a targeted\n      drug available the panel of experts will make an individualized treatment recommendation.\n      The results of the tumor profiling and the individualized treatment recommendation can be\n      shared with the primary oncologist."
        }, 
        "brief_title": "iCAT for Recurrent/Refractory/HR Solid Tumors", 
        "condition": [
            "Pediatric Solid Tumor", 
            "Sarcoma", 
            "Neuroblastoma", 
            "Wilms Tumor"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Wilms Tumor", 
                "Neuroblastoma", 
                "Neoplasms", 
                "Sarcoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "Some cancer-causing gene alterations (such as mutations or copy number alterations) are\n      common or occur repeatedly in different types of cancers. For some of these alterations\n      there are drugs, called targeted drugs that specifically counteract the alteration. In\n      certain cancer types, these targeted drugs are very effective at fighting the cancer.\n\n      A tumor specimen that has been obtained previously or is planned to be obtained as part of\n      clinical care will be used to perform tumor profiling. Additional procedures to obtain tumor\n      will not be performed. An expert panel will review the results of the tumor profiling tests\n      and determine whether a cancer-causing alteration is present and whether an individualized\n      treatment recommendation can be made. If consent to sharing of the tumor profiling results\n      and individualized treatment recommendation is provided then a study physician will discuss\n      the profiling results and the individualized treatment recommendation with the primary\n      oncologist. In addition, the primary oncologist will receive a letter detailing the tumor\n      profiling results and the individualized treatment recommendation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of recurrent, refractory of high risk pediatric solid tumor (excluding\n             brain tumor)\n\n          -  Histologic proof of malignancy at the time of diagnosis or recurrence\n\n          -  Sufficient tumor specimen available for profiling from diagnosis or recurrence, or\n             surgery/biopsy planned for clinical care\n\n        Exclusion Criteria:\n\n          -  Brain tumors"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Pediatric patients with recurrent, refractory or high risk solid tumors"
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01853345", 
            "org_study_id": "11-406"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Refractory", 
            "Recurrent", 
            "High Risk"
        ], 
        "lastchanged_date": "January 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94143"
                    }, 
                    "name": "University of California, San Francisco"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20010"
                    }, 
                    "name": "Children's National Medical center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana-Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Boston Children's Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Individualized Cancer Therapy (iCAT) Recommendation for Patients With Recurrent, Refractory or High Risk Solid Tumors", 
        "overall_official": {
            "affiliation": "Dana-Farber Cancer Institute", 
            "last_name": "Katherine Janeway, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Frequency of a cancer causing actionable alteration and individualized treatment recommendation.", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01853345"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Dana-Farber Cancer Institute", 
            "investigator_full_name": "Katherine Janeway, MD", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Dana-Farber Cancer Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dana-Farber Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "99 Years", 
        "verification_date": "December 2013"
    }
}